Vical's CEO Hosts At Citi 2012 Global Health Care Conference (Transcript)

Vical Incorporated (VICL)

Citi 2012 Global Health Care Conference Call

February 27, 2012 3:30 pm EST

Executives

Vijay B. Samant – President and Chief Executive Officer

Presentation

Vijay B. Samant

Compare to:
Previous Statements by VICL
» Vical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Vical Incorporated at Credit Suisse Group Healthcare Conference Call Transcript
» Vical Incorporated's CEO Discusses Q3 2011 Results - Earnings Call Transcript

People in the audience. So, first of all, I want to thank Citi for inviting us to this conference. They just did a recent financing, so it’s appropriate that they invite us to this conference. Before I begin my formal presentation, let me refer to your Safe Harbor Statements. We may be looking some forward-looking statements. Please refer to our filed SEC documents to fully understand the risk associated in investing with Vical.

For a number of members in the audience, may not know what Vical does? Vical is a biotechnology company, which has a broad pipeline and a substantial commercial opportunity. I think the lead program is Allovectin-7; I am going to spend some time talking about it. It’s a program for cancer immunotherapy. We have Phase 3 pivotal study which is complete, the one-year follow-up and the patient completed by the end of this month, so I will talk more about that timeline, I am sure in the breakout session, there will be a lot of questions in the timeline.

We are very excited about this program by the way, in terms of how this has come about and how we have executed this program. Allovectin-7 dose has been used for melanoma, if I go through the mechanism of the action you will clearly understand; it is applications of all the solid tumor applications. Our next application would be head and neck cancer, so keep your eyes open, as we talk about our data from our melanoma study, so you fully understand how that translates to other solid tumors.

1 2 3 Next › Last »